Luo J - Search Results

1

Integrative analysis of AR-mediated transcriptional regulatory network reveals IRF1 as an inhibitor of prostate cancer progression.

Cheng Y, Wang D, Jiang J, Huang W, Li D, Luo J, Gu W, Mo W, Wang C, Li Y, Gu S, Xu Y. Cheng Y, et al. Among authors: luo j. Prostate. 2020 May;80(8):640-652. doi: 10.1002/pros.23976. Epub 2020 Apr 13. Prostate. 2020. PMID: 32282098

2

Modulation of CXCL14 (BRAK) expression in prostate cancer.

Schwarze SR, Luo J, Isaacs WB, Jarrard DF. Schwarze SR, et al. Among authors: luo j. Prostate. 2005 Jun 15;64(1):67-74. doi: 10.1002/pros.20215. Prostate. 2005. PMID: 15651028

3

GOLPH2 and MYO6: putative prostate cancer markers localized to the Golgi apparatus.

Wei S, Dunn TA, Isaacs WB, De Marzo AM, Luo J. Wei S, et al. Among authors: luo j. Prostate. 2008 Sep 15;68(13):1387-95. doi: 10.1002/pros.20806. Prostate. 2008. PMID: 18543251 Free PMC article.

4

Expression of cancer/testis antigens in prostate cancer is associated with disease progression.

Suyama T, Shiraishi T, Zeng Y, Yu W, Parekh N, Vessella RL, Luo J, Getzenberg RH, Kulkarni P. Suyama T, et al. Among authors: luo j. Prostate. 2010 Dec 1;70(16):1778-87. doi: 10.1002/pros.21214. Prostate. 2010. PMID: 20583133 Free PMC article.

5

A snapshot of the expression signature of androgen receptor splicing variants and their distinctive transcriptional activities.

Hu R, Isaacs WB, Luo J. Hu R, et al. Among authors: luo j. Prostate. 2011 Nov;71(15):1656-67. doi: 10.1002/pros.21382. Epub 2011 Mar 28. Prostate. 2011. PMID: 21446008 Free PMC article.

6

Cost-Savings Analysis of AR-V7 Testing in Patients With Metastatic Castration-Resistant Prostate Cancer Eligible for Treatment With Abiraterone or Enzalutamide.

Markowski MC, Frick KD, Eshleman JR, Luo J, Antonarakis ES. Markowski MC, et al. Among authors: luo j. Prostate. 2016 Dec;76(16):1484-1490. doi: 10.1002/pros.23232. Epub 2016 Jul 12. Prostate. 2016. PMID: 27404039 Free PMC article.

7

Germline mutations in PPFIBP2 are associated with lethal prostate cancer.

Wu Y, Yu H, Zheng SL, Feng B, Kapron AL, Na R, Boyle JL, Shah S, Shi Z, Ewing CM, Wiley KE, Luo J, Walsh PC, Carter HB, Helfand BT, Cooney KA, Xu J, Isaacs WB. Wu Y, et al. Among authors: luo j. Prostate. 2018 Dec;78(16):1222-1228. doi: 10.1002/pros.23697. Epub 2018 Jul 24. Prostate. 2018. PMID: 30043417

8

A novel androgen-reduced prostate-specific lncRNA, PSLNR, inhibits prostate-cancer progression in part by regulating the p53-dependent pathway.

Wang D, Wan X, Zhang Y, Kong Z, Lu Y, Sun X, Huang Y, Ji C, Li D, Luo J, Gu W, Wang C, Li Y, Xu Y. Wang D, et al. Among authors: luo j. Prostate. 2019 Sep;79(12):1362-1377. doi: 10.1002/pros.23840. Epub 2019 Jul 3. Prostate. 2019. PMID: 31269242

9

A pilot study of prostate-specific membrane antigen (PSMA) dynamics in men undergoing treatment for advanced prostate cancer.

Paller CJ, Piana D, Eshleman JR, Riel S, Denmeade SR, Isaacsson Velho P, Rowe SP, Pomper MG, Antonarakis ES, Luo J, Eisenberger MA. Paller CJ, et al. Among authors: luo j. Prostate. 2019 Oct;79(14):1597-1603. doi: 10.1002/pros.23883. Epub 2019 Jul 30. Prostate. 2019. PMID: 31361358 Free PMC article.

10

Androgen receptor variant-driven prostate cancer II: advances in laboratory investigations.

Lu C, Brown LC, Antonarakis ES, Armstrong AJ, Luo J. Lu C, et al. Among authors: luo j. Prostate Cancer Prostatic Dis. 2020 Sep;23(3):381-397. doi: 10.1038/s41391-020-0217-3. Epub 2020 Mar 5. Prostate Cancer Prostatic Dis. 2020. PMID: 32139878 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

23,178 results

Search Page

Filters